The Center for Regenerative Biotherapeutics has launched state-of-the-art platforms for the express purpose of translating new knowledge into tailored regenerative solutions. A Board of Governors designated initiative, the Advanced Product Incubator (API), aims to establish cell-free platforms to develop safe and effective regenerative therapies.
The API infrastructure participates in the manufacturing of a spectrum of clinically relevant therapies spanning from devices to biological and pharmaceutical agents. Built according to Current Good Manufacturing Practices (CGMP), this multidisciplinary, first-of-its-kind facility bridges teams of researchers and physicians with scientific and industry experts to accelerate product development.
The API design fosters the translation of laboratory discoveries into clinical grade curative products developed with the lowest possible risk to patients.
